Pharmacokinetics in mice of a [3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid

Journal of Controlled Release

Volumn 41, Issue 1-2, 1996, Pages 121-130

  Bennett, C Frank ^a   Zuckerman, Joan E ^a   Kornbrust, Doug ^a   Sasmor, Henri ^a   Leeds, Janet M ^a   Crooke, Stanley T ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense oligonucleotide; Cationic lipid; Liposome; Pharmacokinetics

Indexed keywords

1,2 DIOLEOYLGLYCERO 3 PHOSPHOETHANOLAMINE; ANTISENSE OLIGONUCLEOTIDE; CATION; ISIS 3082; LIPID; LIPOSOME; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; RADIOISOTOPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; ELECTRICITY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; LIVER; LUNG; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; SKIN; SPLEEN; TISSUE DISTRIBUTION;

EID: 0030222182     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-3659(96)01362-4     Document Type: Conference Paper

References (52)

1. [1] S.T. Crooke, Therapeutic applications of oligonucleotides, Annu. Rev. Pharmacol. Toxicol. 32 (1992) 329-376.
2. [2] C.A. Stein and Y.-C. Cheng, Antisense oligonucleotides as therapeutic agents-Is the bullet really magical? Science 261 (1993) 1004-1012.
3. [3] S.T. Crooke, Therapeutic Applications of Oligonucleotides, R.G. Landes Company, Austin, 1995.
4. [4] R.M. Crooke, Cellular uptake, distribution and metabolism of phosphorothioate, phosphodiester, and methylphosphonate oligonucleotides, in: S.T. Cooke and B. Lebleu (Eds.), Antisense Research and Applications, CRC Press, Boca Raton, FL, 1993, pp. 427-449.
5. [5] W.-Y. Gao, C. Storm, W. Egan and Y.-C. Cheng, Cellular pharmacology of phosphorothioate homooligodeoxynucleotides in human cells, Mol. Pharmacol. 43 (1993) 45-50.
6. [6] S. Wu-Pong, T.L. Weiss and C.A. Hunt, Antisense c-myc oligonucleotide cellular uptake, Pharm. Res. 9 (1992) 1010-1017.
7. [7] R.M. Crooke, M.J. Graham, M.E. Cooke and S.T. Crooke, In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides, J. Pharm. Exp. Ther. 275 (1995) 462-473.
8. [8] C.A. Stein, J.L. Tonkinson, L.-M. Zhang, L. Yakubov, J. Gervasoni, R. Taub and S.A. Rotenberg, Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells, Biochemistry 32 (1993) 4855-4861.
9. [9] C. Beltinger, H.U. Saragovi, R.M. Smith, L. LeSauteur, N. Shah, L. DeDionisio, L. Christensen, A. Raible, L. Jarett and A.M. Gewirtz, Binding, uptake and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides, J. Clin. Invest. 95 (1995) 1814-1823.
10. [10] S.L. Loke, C.A. Stein, X.H. Zhang, K. Mori, M. Nakanishi, C. Subasinghe, J.S. Cohen and L.M. Neckers, Characterization of oligonucleotide transport into living cells, Proc. Natl. Acad. Sci. USA 86 (1989) 3474-3478.
11. [11] L.A. Yakubov, E.A. Deeva, V.F. Zarytova, E.M. Ivanova, A.S. Ryte, L.V. Yurchenko and V.V. Vlassov, Mechanism of oligonucleotide uptake by cells: Involvement of specific receptors? Proc. Natl. Acad. Sci. USA 86 (1989) 6454-6458.
12. [12] Y. Shoji, S. Akhtar, A. Periasamy, B. Herman and R.L. Juliano, Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages, Nucleic Acids Res. 19 (1991) 5543-5550.
13. [13] C.F. Bennett, M.-Y. Chiang, H. Chan, J.E.E. Shoemaker and C.K. Mirabelli, Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides, Mol. Pharmacol. 41 (1992) 1023-1033.
14. [14] T.L. Fisher, T. Terhorst, X. Cao and R.W. Wagner, Intracellular disposition and metabolism of fluorescently-labeled unmodified and modified oligonucleotides miroinjected into mammalian cells, Nucleic Acids Res. 21(16) (1993) 3857-3865.
15. [15] S.B. Noonberg, M.R. Garovoy and C.A. Hunt, Characteristics of oligonucleotide uptake in human keratinocyte cultures, J. Invest. Dermatol. 101 (1993) 727-731.
16. [16] F.O. Nestle, R.S. Mitra, C.F. Bennett, H. Chan and B.J. Nickoloff, Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes, J. Invest. Dermatol. 103 (1994) 569-575.
17. [17] D.J. Chin, G.A. Green, G. Zon, F.C. Szoka, Jr. and R.M. Straubinger, Rapid nuclear accumulation of injected oligodeoxyribonucleotides, N. Biol. 2 (1990) 1091-1100.
18. [18] J.P. Leonetti, N. Mechti, G. Degols, C. Gagnor and B. Lebleu, Intracellular distribution of microinjected antisense oligonucleotides, Proc. Natl. Acad. Sci. USA 88 (1991) 2702-2706.
19. [19] M.-Y. Chiang, H. Chan, M.A. Zounes, S.M. Freier, W.F. Lima and C.F. Bennett, Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms, J. Biol. Chem. 266 (1991) 18162-18171.
20. [20] C.F. Bennett, M.-Y. Chiang, H. Chan and S. Grimm, Use of cationic lipids to enhance the biological activity of antisense oligonucleotides, J. Liposome Res. 3 (1993) 85-102.
21. [21] N.M. Dean, R. McKay, T.P. Condon and C.F. Bennett, Inhibition of protein kinase C-a expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters, J. Biol. Chem. 269 (1994) 16416-16424.
22. [22] S. Agrawal, J. Temsamani and J.Y. Tang, Pharmacokinetics, biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice, Proc. Natl. Acad. Sci. USA 88 (1991) 7595-7599.
23. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats, J. Pharmacol. Exp. Ther. 267 (1993) 1181-1190.
24. [24] P.A. Cossum, L. Truong, S.R. Owens, P.M. Markham, J.P. Shea and S.T. Crooke, Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats, J. Pharm. Exp. Ther. 269 (1994) 89-94.
25. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate, Mol. Pharmacol. 45 (1994) 932-943.
26. 3H-labeled oligonucleotides. II. 3′,5-blocked oligonucleotides, Mol. Pharmacol. 47 (1995) 636-646.
27. [27] S. Agrawal, J. Temsamani, W. Galbraith and J. Tang, Pharmacokinetics of antisense oligonucleotides, Clin. Pharmacokinet. 28 (1995) 7-16.
28. [28] S.K. Srinivasan and P. Iversen, Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides, J. Clin. Lab. Anal. 9 (1995) 129-137.
29. [29] S.T. Crooke, L.R. Grillone, A. Tendolkar, A. Garrett, M.J. Fratkin, J. Leeds and W.H. Barr, A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts, Clin. Pharm. Ther. 56 (1994) 641-646.
30. [30] M.J. Graham, S.M. Freier, R.M. Crooke, D.J. Ecker, R.N. Maslova and E.A. Lesnik, Tritium labeling of antisense oligonucleotides by exchange with tritiated water, Nucleic Acids Res. 21 (1993) 3737-3743.
31. [31] S.M. Stepkowski, Y. Tu, T.P. Condon and C.F. Bennett, Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities, J. Immunol. 153 (1994) 5336-5346.
32. [32] J.H. Felgner, R. Kumar, C.N. Sridhar, C.J. Wheeler, Y.J. Tsai, R. Border, P. Ramsey, M. Martin and P.L. Felgner, Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations, J. Biol. Chem. 269 (1994) 2550-2561.
33. [33] H. Gershon, R. Ghirlando, S.B. Guttman and A. Minsky, Mode of formation and structural features of DNA-cationic liposome complexes used for transfection, Biochemistry 32 (1993) 7143-7151.
34. [34] I. Jääskeläinen, J. Mönkkönen and A. Urtti, Oligonucleotide-cationic liposome interactions. A physicochemical study, Biochim. Biophys. Acta Bio-Membr. 1195 (1994) 115-123.
35. [35] C.F. Bennett, S. Grimm, J. Felgner, C.N. Sridhar, C.J. Wheeler and P.L. Felgner, Enhanced activity of antisense oligonucleotides with novel cationic liposome formulations, Biochim. Biophs. Acta (1995).
36. [36] S.L. Beaucage and M.H. Caruthers. Deoxynucleoside phosphoramidites. A new class of key intermediates for deoxypolynucleotide synthesis, Tetrahedron Lett. 22 (1981) 1859-1862.
37. [37] S.L. Beaucage and R.P. Iyer, The synthesis of modified oligonucleotides by the phosphoramidite approach and their applications, Tetrahedron 49 (1993) 6123-6194.
38. [38] R.P. Iyer, L.R. Phillips, W. Egan, J.B. Regan and S.L. Beaucage, The automated synthesis of sulfur-containing oligodeoxyribonucleotides using 3H-1,2-benzodithiol-3-one 1,1-dioxide as a sulfur-transfer reagent, J. Org. Chem. 55 (1990) 4693-4699.
39. [39] N. Zhu, D. Liggitt and R. Debs, Systemic gene expression after intravenous DNA delivery into adult mice, Science 261 (1993) 209-211.
40. [40] R.I. Mahato, K. Kawabata, Y. Takakura and M. Hashida, In vivo disposition characteristics of plasmid DNA complexed with cationic liposomes, J. Drug Target. 3 (1995) 149-157.
41. [41] N.M. Dean and R. McKay, Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides, Proc. Natl. Acad. Sci. USA 91 (1994) 11762-11766.
42. [42] I. Kitajima, T. Shinohara, J. Bilakovics, D.A. Brown, X. Xiao and M. Nerenberg, Ablation of transplanted HTLV-1 tax-transformed tumors in mice by antisense inhibition of NF-KB, Science 258 (1992) 1792-1795.
43. [43] K.A. Higgins, J.R. Perez, T.A. Coleman, K. Dorshkind, W.A. McComas, U.M. Sarmiento, C.A. Rosen and R. Narayanan, Antisense inhibition of the p65 subunit of NF-kappaB blocks tumorigenicity and causes tumor regression, Proc. Natl. Acad. Sci. USA 90 (1993) 9901-9905.
44. [44] N. Hijiya, J. Zhang, M.Z. Ratajczak, J.A. Kant, K. DeRiel, M. Herlyn, G. Zon and A.M. Gewirtz, Biologic and therapeutic significance of MYB expression in human melanoma, Proc. Natl. Acad. Sci. USA 91 (1994) 4499-4503.
45. [45] T. Skorski, M. Nieborowska-Skorska, N.C. Nicolaides, C. Szczylik, P. Iversen, R.V. Iozzo, G. Zon and B. Calabretta, Suppression of Philadelphia leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide, Proc. Natl. Acad. Sci. USA 91 (1994) 4504-4508.
46. [46] V.L. Woodburn, J.C. Hunter, C. Durieux, J.A. Poat and J. Hughes, The effect of C-fos antisense in the formalin-paw test, Regul. Pept. 54 (1994) 327-328.
47. 2 receptors: Behavioral correlates, Neurosci. Lett. 161 (1993) 223-226.
48. 1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine, J. Pharmacol. Exp. Ther. 271 (1994) 1462-1470.
49. [49] M.S. Kindy, NMDA receptor inhibition using antisense oligonucleotides prevents delayed neuronal death in gerbil hippocampus following cerebral ischemia, Neurosci. Res. Commun. 14 (1994) 175-183.
50. [50] W.M. Quinlan, N.A. Doyle, T. Kumasaka, E. Wancewicz, C.F. Bennett and C.M. Doerschuk, The effect of ICAM-1 anti-sense oligonucleotides on the expression of ICAM-1 mRNA induced by E. coli endotoxin, Am. Rev. Respir. Dis. 150 (1994) A325.
51. [51] C.F. Bennett, D. Kornbrust, S. Henry, S. Dutson, W. Hall and H.I. Jacoby, An ICAM-1 antisense oligonucleotide, ISIS 3082, prevents and reverses dextran sulfate sodium-induced colitis in mice, (1995) manuscript submitted.
52. [52] S.T. Crooke, M.J. Graham, J.E. Zuckerman, D. Brooks, B.S. Conklin, L.L. Cummins, M.J. Greig, C.J. Guinosso, D. Kornbrust, M. Manoharan, H.M. Sasmor, T. Schleich, K.L. Tivel and R.H. Griffey, Pharmacokinetic properties of several novel oligonucleotide analogs in mice, J. Pharmacol. Exp. Ther. (1995) in press.